KGF pretreatment decreases B7 and granzyme B expression and hastens repair in lungs of mice after allogeneic BMT

Angela Panoskaltsis-Mortari1, David H. Ingbar2, Patricia Jung2, Imad Y. Haddad2, Peter B. Bitterman2, O. Douglas Wangensteen3, Catherine L. Farrell4, David L. Lacey4, and Bruce R. Blazar1

1 Department of Pediatrics, Division of Hematology-Oncology and Bone Marrow Transplantation, and Departments of 2 Pulmonary Critical Care Medicine and 3 Physiology, University of Minnesota, Minneapolis, Minnesota 55455; and 4 Amgen, Thousand Oaks, California 91320


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We investigated keratinocyte growth factor (KGF) as a pretreatment therapy for idiopathic pneumonia syndrome (IPS) generated as a result of lung damage and allogeneic T cell-dependent inflammatory events occurring in the early peri-bone marrow (BM) transplant (BMT) period. B10.BR (H2k) recipient mice were transplanted with C57BL/6 (H2b) BM with spleen cells after lethal irradiation with and without cyclophosphamide conditioning with and without subcutaneous KGF pretreatment. KGF-pretreated mice had fewer injured alveolar type II (ATII) cells at the time of BMT and exhibited ATII cell hyperplasia at day 3 post-BMT. The composition of infiltrating cells on day 7 post-BMT was not altered by KGF pretreatment, but the frequencies of cells expressing the T-cell costimulatory molecules B7.1 and B7.2 and mRNA for the cytolysin granzyme B (usually increased in IPS) were decreased by KGF. Sera from KGF-treated mice had increases in the Th2 cytokines interleukin (IL)-4, IL-6, and IL-13 4 days after cessation of KGF administration (i.e., at the time of BMT). These data suggest that KGF hinders IPS by two modes: 1) stimulation of alveolar epithelialization and 2) attenuation of immune-mediated injury as a consequence of failure to upregulate cytolytic molecules and B7 ligand expression and the induction of anti-inflammatory Th2 cytokines in situ.

bone marrow transplant; keratinocyte growth factor; type II pneumocytes; cytokines; macrophages; costimulatory molecules


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

IDIOPATHIC PNEUMONIA SYNDROME (IPS) is a significant cause of non-graft-versus-host disease (non-GVHD) deaths after bone marrow (BM) transplant (BMT) and accounts for the majority of complications involving the lung in the early post-BMT period (9). Intense conditioning regimens lead to a higher incidence of pulmonary toxicity in BMT recipients but are beneficial in preventing relapse and promoting BM engraftment (11, 20, 26, 43, 47, 55). Greater severity of GVHD post-BMT also increases the risk of developing IPS. In a mouse model study evaluating the contributions of preconditioning with total body irradiation (TBI) with and without cyclophosphamide (Cy) and allogeneic T cells to the generation of IPS, we reported that the severity of early post-BMT IPS injury was dependent on allogeneic T cells and potentiated by Cy (42). IPS injury was associated with the recruitment of host monocytes and donor T cells into the lung in response to tissue injury (42). The association of IPS with host monocyte infiltration and the dependence on allogeneic T cells has since been confirmed independently by two other laboratories (see Refs. 10, 13). The manifestations of lung injury we previously described included epithelial cell injury, increased wet and dry lung weights, and decreased specific lung compliance and lung capacity. Because almost all of the macrophages in the lung are host derived at this early time point post-BMT (42), measures to hinder the activation of immune effectors of the recipient may present alternative strategies for the prevention of IPS.

In response to injury in the lung, type II alveolar epithelial (ATII) cells proliferate and differentiate to replace dying type I epithelial pneumocytes (27a). The degree of lung injury ultimately manifested is to a large extent dependent on the ability of type II cells to effectively carry out this process to reepithelialize the alveolar membrane. Acute injury also releases intracellular contents that trigger acute-phase reactants, cytokines, and chemokines to initiate the inflammatory response and tissue repair process. This cascade can involve the induction of selectins and adhesion molecules leading to transmigration of inflammatory cells into the alveolar space. Acute lung inflammation is correlated with increased levels of proinflammatory cytokine mRNA in the lung (31, 44, 46, 53, 54, 58). Studies of bronchoalveolar lavage (BAL) fluid in mice following BMT across minor histocompatible differences demonstrated that increased levels of tumor necrosis factor (TNF)-alpha and endotoxin [lipopolysaccharide (LPS)] at 6 wk post-BMT were associated with lung damage and IPS generation (12). In addition, we also described that the frequency of cells expressing T-cell costimulatory B7 molecules increased in the lung, as did the frequency of cells expressing mRNA for transforming growth factor (TGF)-beta (a monocyte chemoattractant), IL-1beta , and TNF-alpha (42). This sets the stage for an immune-mediated attack on lung tissue by allospecific donor T cells, since activation of monocytes and their subsequent increased expression of B7 regulates the generation of cytotoxic T lymphocytes (CTL) that express the cytolysins granzymes A and B and, therefore, may contribute to the amplification of tissue injury.

KGF is a mediator of epithelial cell proliferation (24) and mesenchymal-epithelial interactions (23) as well as a growth factor for type II pneumocytes (39, 52). KGF is protective against chemotherapy- and radiation-induced injury in various rodent models (22, 51). We recently reported that in vivo administration of exogenous KGF, completed before conditioning, ameliorated GVHD-induced weight loss and mortality following allogeneic BMT in mice (41). In addition, KGF diminished GVHD-induced lesions in the target organs, especially the skin and lung, of long-term allogeneic BMT survivors. The protective effect of KGF on GVHD also has been confirmed recently in another murine model (34). In investigations targeting pulmonary injury, KGF was protective in lethal models of radiation-, hyperoxia-, acid-, and bleomycin-induced lung injury in rats (28, 60, 62), possibly by facilitating repair of DNA damage in alveolar epithelial cells (50, 57). Furthermore, KGF induces increased lung surfactant levels (49), potentiates alveolar fluid clearance by increasing Na+-K+-ATPase activity (6), decreases hyperoxia-induced apoptosis of (ATII) cells, and may detoxify reactive oxygen species generated by injured cells (reviewed in Ref. 56). Here, we report the effects of KGF on the IPS-inducing inflammatory events in the lung. The goal of this study is to investigate some potential mechanisms of KGF-mediated amelioration of lung injury in the peri-BMT period. Our data indicate that KGF diminishes IPS injury, at least in part, by dampening the immune system response to chemoradiotherapy-induced lung damage and by accelerating repair of the damaged tissue.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Mice. B10.BR (H2k) and C57BL/6 (H2b) mice were purchased from Jackson Laboratories (Bar Harbor, ME). Mice were housed in microisolator cages in the SPF facility of the University of Minnesota and cared for according to the Research Animal Resources guidelines of our institution. For BMT, donors were 8-12 wk of age and recipients were used at 8-10 wk of age.

KGF production. Recombinant human KGF produced in Escherichia coli was prepared as previously described (52) at Amgen (Thousand Oaks, CA).

Pre-BMT conditioning. B10.BR mice received PBS or KGF (5 mg · kg-1 · day-1 sc) on days -6, -5, and -4 pre-BMT. Mice were then segregated into those receiving either PBS or Cy (Cytoxan; Bristol Myers Squibb, Seattle, WA), 120 mg · kg-1 · day-1, as a conditioning regimen pre-BMT on days -3 and -2. All mice were lethally irradiated on the day before BMT (7.5-Gy TBI) by X-ray at a dose rate of 0.41 Gy/min as described (3).

BMT. Our BMT protocol has been described previously (5). Briefly, donor C57BL/6 BM was T cell depleted (TCD) with anti-Thy 1.2 monoclonal antibody (MAb) (clone 30-H-12, rat IgG2b, kindly provided by Dr. David Sachs, Charlestown, MA) plus complement (Nieffenegger, Woodland, CA). Recipient mice were transplanted via caudal vein with 20 × 106 TCD C57BL/6 (H-2b) marrow with or without 15 × 106 NK cell-depleted (PK136, anti-NK1.1 + complement) spleen cells (BMS) as a source of IPS-causing T cells.

Electron microscopy. This was performed as previously described (42). After inflation to ~20 cmH2O by hand, 2- to 3-mm3 pieces of lung tissue were fixed in 2% glutaraldehyde for 1-2 days at 4°C followed by postfixation in 1% osmium tetroxide (EM Sciences, Fort Washington, PA) in 0.1 M sodium cacodylate buffer for 1 h, dehydrated in graded ethanol and propylene oxide, and embedded in Epon 812 (EM Sciences). Sections were cut at a thickness of 600 nm, stained with uranyl acetate-lead citrate (EM Sciences), and examined with a Philips 301 electron microscope. A minimum of 17 prints (maximum 39) taken at a magnification of ×4,200 from multiple sections from 2 representative mice of each group at day 0 and day 3 post-BMT were examined by three observers in coded fashion. The number of type II cells present (based on morphological appearance and presence of lamellar bodies) was expressed as a percent of total nucleated cells.

Frozen tissue preparation. After death of the mouse at either day 0, 3, or 7, a mixture of 0.5 ml of optimal cutting temperature compound (Miles, Elkhart, IN) and PBS (3:1) was infused via the trachea into the lungs. Lungs were snap-frozen in liquid nitrogen and stored at -80°C.

Immunohistochemistry. After fixation in acetone, cryosections (4 µm) were immunoperoxidase stained using biotinylated MAbs with avidin-biotin blocking reagents, ABC-peroxidase conjugate, and diaminobenzidine chromogenic substrate purchased from Vector Laboratories (Burlingame, CA) essentially as described (4). The biotinylated MAbs used were as follows: anti-CD4 (clone GK1.5), anti-CD8 (clone 2.43), anti-Mac-1 (clone M1/70), anti-Gr-1 (clone RB6-8C5), anti-I-Ak (clone 11-5.2), anti-B7.1 (clone 1G10), and anti-B7.2 (clone GL1), all purchased from PharMingen (San Diego, CA). Representative sections from each tissue block were stained with hematoxylin and eosin for histopathological assessment. The number of positive cells in the lung was quantitated as the percent of nucleated cells under ×200 magnification (×20 objective lens). Four fields per lung were evaluated.

In situ hybridization. This procedure has been described in detail elsewhere (40). Cryosections (4 µm) were hybridized with digoxigenin-labeled antisense RNA probes. The corresponding ribonucleotide sequences used were 80-910 bp for granzyme A and 239-775 bp for granzyme B. Immunological detection of digoxigenin-labeled RNA duplexes was accomplished with anti-digoxigenin antibody (alkaline phosphatase conjugated; Boehringer Mannheim). After color development, sections were mounted in Crystalmount (Biomeda, Foster City, CA). Positive cells were quantitated as described above.

Serum cytokine level determination. At the time of death of the mouse, blood was collected by cardiac puncture and placed immediately at 4°C; the serum was separated at 4°C and stored at -80°C. Serum levels of IL-1beta , IL-4, IL-6, IL-10, IL-13, interferon (IFN)-gamma , and TNF-alpha were determined by ELISA using commercial kits (R&D Systems, Minneapolis, MN).

Statistical analysis. Data were analyzed by ANOVA (Dunnett's test) or Student's t-test. Probability (P) values less than or equal to 0.05 were considered statistically significant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

KGF preconditioning preserves ATII cells in the lung after allogeneic BMT. To determine whether KGF administration (subcutaneous on days -6, -5, and -4 pre-BMT) would affect early lung injury parameters documented previously by this laboratory (42), experiments were set up to compare the effect of KGF in the context of TBI or Cy/TBI conditioning as well as with (BMS) or without (BM) the addition of a 100% lethal dose of allogeneic spleen cells (see Fig. 1). B10.BR recipients were infused with C57BL/6 cells and killed on either day 0 (pre-BMT) or day 3 post-BMT, and lungs were examined by electron microscopy. We chose days 0 and 3 for two reasons: 1) because the allogeneic cells are infused on day 0, they would be exposed to early manifestations of conditioning-induced injury and any potential tissue-altering effects of KGF at this time; and 2) endothelial and epithelial cell injury are evident at least as early as day 3 by electron microscopy and represent the end of the first wave of host monocyte infiltration (42).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Keratinocyte growth factor (KGF) treatment and conditioning schedule for bone marrow (BM) transplant (BMT) experiments. KGF (5 mg · kg-1 · day-1) or PBS was administered subcutaneously to B10.BR recipients on days -6, -5, and -4. Mice were then further segregated into those receiving cyclophosphamide (Cy; 120 mg · kg-1 · day-1) or PBS intraperitoneally on days -3 and -2. All recipients were irradiated (7.5 Gy) on the day before transplant (day -1). Groups were segregated into those receiving C57BL/6 BM alone or BM with allogeneic spleen cells (BMS) intravenously. Lungs were harvested for analysis on days 0 (before BMT), 3, and 7 post-BMT. EM, electron microscopy; IHC, immunohistochemistry; ISH, in situ hybridization; TBI, total body inrradiation.

At the time of BMT (day 0), the percentage of type II cells in the alveolar areas, as a percent of nucleated cells counted by light microscopy of hematoxylin and eosin-stained lung sections, was not changed significantly by subcutaneous KGF pretreatment for any treatment group (see Figs. 2 and 3). This was also confirmed by counting ATII cells from electron micrographs (data not shown). Occasional small foci of ATII cell clusters and diffuse cuboidal growth were seen in hematoxylin and eosin-stained sections of lungs from KGF-pretreated mice (see Fig. 3, blue and green arrows), but because these features were sparse, they did not amount to a significant increase in ATII number. However, because evidence of injured ATII cells could be seen to some degree by light microscopy (shown in Fig. 3, PBS/TBI and PBS/Cy/TBI photos as arrows pointing to swollen-looking ATII cells), we decided to determine whether KGF pretreatment affected the ratio of noninjured to injured ATII cells by examination of electron micrographs from which injured cells are better discerned from noninjured cells. Figure 2 shows that, from the representative mice we examined (n = 2/group), the percent of intact, noninjured type II cells increased by 70% with KGF pretreatment regardless of conditioning regimen, consistent with the target cell specificity of KGF and its known cytoprotective effects (52, 62). Morphological criteria used to identify injured ATII cells included decreased density of intracellular components (edema), swollen mitochondria, vacuolation, and lack of continuous discrete membranes (representative examples are shown in Fig. 4). Formal morphometry was not performed because we only wished to know whether there was a change in the ratio of noninjured to injured ATII cells. KGF pretreatment did not prevent the minor focal irradiation-induced edema of the endothelium we previously described (42). By day 3 post-BMT, all groups receiving allogeneic T cells exhibited increased cellularity of the interstitium. Surprisingly at this time, KGF-pretreated mice additionally exhibited ATII epithelial cell hyperplasia compared with non-KGF-pretreated mice, regardless of whether these mice also received allogeneic spleen cells (day 3 Cy/TBI BMS mice shown in Figs. 5 and 6). KGF pretreatment prevented the 25% decrease in ATII cell number seen in BMS mice not given KGF (see Fig. 7). These findings suggest that KGF mediated the preservation and, perhaps, proliferation of type II cells that is necessary for their subsequent differentiation to replace injured type I cells and maintain the integrity of the alveolar epithelium.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   KGF pretreatment does not affect the number of alveolar type II (ATII) cells by the day of BMT (day 0) but does preserve ATII cell integrity. B10.BR recipient mice were preconditioned with TBI (day -1) with and without Cy (days -3 and -2). Groups received KGF (5 mg · kg-1 · day-1) on days -6, -5, and -4 pre-BMT. Lung tissues were harvested on day 0 before BMT. Data are expressed as percent of nucleated cells displaying ATII characteristics (rounded nucleus, abundant cytoplasm, located at alveolar septal vertices) as determined by counting hematoxylin and eosin-stained lung cryosections under light microscope using ×40 objective lens with ×10 ocular. Mean values ± SD are for 3 mice per group from 2 representative experiments. The proportion of noninjured vs. injured ATII cells was determined by counting from electron micrographs such as those shown in Fig. 4 that were generated from 600-nm sections photographed under ×4,200 magnification.



View larger version (108K):
[in this window]
[in a new window]
 
Fig. 3.   KGF-pretreated mice exhibit small focal clusters and diffuse cuboidal proliferation of ATII cells on day 0. B10.BR recipient mice were preconditioned with TBI (day -1) with and without Cy (days -3 and -2). Groups received KGF (5 mg · kg-1 · day-1) on days -6, -5, and -4 pre-BMT. Lung tissues were harvested on day 0 before BMT. Lung cryosections (4 µm) were stained by hematoxylin and eosin, and black arrows point to cells displaying ATII characteristics (rounded nucleus, abundant cytoplasm, located at alveolar septal vertices). Blue arrows point to small focal ATII cell clusters; green arrows point to diffuse cuboidal proliferation. Resolution power is of ×20 objective lens for wide-view image under light microscope.



View larger version (100K):
[in this window]
[in a new window]
 
Fig. 4.   Representative electron micrographs of lungs from day 0 before BMT of TBI or Cy/TBI conditioned mice with (B and D) or without (A and C) KGF pretreatment. KGF-pretreated mice exhibited fewer injured type II cells compared with control vehicle recipients. Salient features and treatment groups are indicated. a, Alveolar space; 1, type I epithelial cell; 2, type II epithelial cell; m, macrophage (magnification ×4,200; bar = 5 µm). E and F are examples of injured and noninjured ATII cells, respectively (magnification ×22,000; bar = 1 µm).



View larger version (79K):
[in this window]
[in a new window]
 
Fig. 5.   KGF-pretreated mice exhibit hyperplasia of ATII cells on day 3 post-BMT. B10.BR recipient mice were preconditioned with TBI (day -1) with and without Cy (days -3 and -2) and given C57BL/6 BM with spleen cells (BMS) on the day of BMT (day 0). Groups received KGF (5 mg · kg-1 · day-1) on days -6, -5, and -4 pre-BMT. Lung tissues were harvested on day 3 post-BMT. Lung cryosections (4 µm) were stained by hematoxylin and eosin, and black arrows point to cells displaying ATII characteristics (rounded nucleus, abundant cytoplasm, located at alveolar septal vertices). Resolution power is of ×20 objective lens for wide-view image under light microscope.



View larger version (67K):
[in this window]
[in a new window]
 
Fig. 6.   Representative electron micrographs of lungs from day 3 post-BMT of Cy/TBI conditioned BMS recipient mice with and without KGF pretreatment. Type II cell hyperplasia was apparent in all mice pretreated with KGF (Cy/TBI BMS shown). Salient features and treatment groups are indicated. a, Alveolar space; 1, type I epithelial cell; 2, type II epithelial cell; m, macrophage. Magnification ×4,200, bar = 5 µm.



View larger version (33K):
[in this window]
[in a new window]
 
Fig. 7.   KGF-pretreated mice have increased numbers of ATII cells on day 3 post-BMT. B10.BR recipient mice were preconditioned with TBI (day -1) with and without Cy (days -3 and -2) and given C57BL/6 BM alone or with spleen cells (BMS) on the day of BMT (day 0). Groups received KGF (5 mg · kg-1 · day-1) on days -6, -5, and -4 pre-BMT. Lung tissues were harvested on day 3 post-BMT. Data are expressed as percent of nucleated cells displaying ATII characteristics (rounded nucleus, abundant cytoplasm, located at alveolar septal vertices) as determined by counting hematoxylin and eosin-stained lung cryosections under light microscope using ×40 objective lens with ×10 ocular. Mean values ± SD are for 3 mice per group from 2 representative experiments. * P < 0.05 vs. non-KGF counterpart.

KGF preconditioning attenuates B7 costimulatory molecule expression and the induction of the cytolysin granzyme B in the lung on day 7 post-BMT. In the initial description of our murine IPS model, we showed that the pulmonary cellular infiltrate was composed of CD4+ and CD8+ donor T cells, neutrophils, and host monocytes/macrophages. Therefore, we sought to determine the effects of KGF on the cellular inflammatory response to Cy-, TBI-, and T cell-mediated lung injury on day 7 post-BMT. Day 7 was chosen because we previously demonstrated that lung dysfunction and inflammatory infiltrates were evident at this time (42). Although conditioning caused a transient increase in host monocytes, the prolonged second wave of host monocyte infiltration and induction of B7 expression was T cell dependent. Figure 8 shows that KGF pretreatment does not significantly affect the composition of the cellular infiltrate in the lung at day 7 post-BMT as assessed by immunohistochemical staining of cryosections. Regardless of conditioning regimen, KGF attenuated the expression of B7.1 (CD80) and B7.2 (CD86), molecules, which are costimulatory for T cells, while not affecting the frequency of cells expressing host major histocompatibility complex (MHC) class II (I-Ak) as shown in Fig. 9 (from the same pool of experiments). KGF pretreatment did not affect the lack of donor MHC class II (I-Ab) cells, characteristic of our IPS model at this day 7 time point (42) (data not shown). Representative photomicrographs of B7.1 staining are shown in Fig. 10.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 8.   KGF does not affect the cellular composition of lung infiltrates post-BMT. Expression of Mac-1, CD4, CD8, and Gr-1 was determined by immunoperoxidase staining with biotinylated monoclonal antibodies. B10.BR recipient mice were preconditioned with TBI (day -1) with and without Cy (days -3 and -2) and given C57BL/6 BM with spleen cells (BMS) on the day of BMT (day 0). Groups received KGF (5 mg · kg-1 · day-1) on days -6, -5, and -4 pre-BMT. Lung tissues were harvested on day 7 post-BMT. Data are expressed as percent of nucleated cells expressing the surface marker in the lung as determined by counting 4 fields per lung section under light microscope. Mean values ± SE are for 3-5 mice per group from 3 representative experiments.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 9.   KGF attenuates expression of B7.1 and B7.2, while not affecting host major histocompatibility complex (MHC) class II (I-Ak), as determined by immunoperoxidase staining with biotinylated monoclonal antibodies. B10.BR recipient mice were preconditioned with TBI (day -1) with and without Cy (120 mg · kg-1 · day-1, days -3 and -2) and given C57BL/6 BM with 15 × 106 spleen cells (BMS) on the day of BMT (day 0). Groups received KGF (5 mg · kg-1 · day-1) on days -6, -5, and -4 pre-BMT. Lung tissues were harvested on day 7 post-BMT. Data are expressed as percent of nucleated cells expressing the indicated surface marker in the lung as determined by counting 4 fields per lung section under light microscope. Mean values ± SE are for 4-6 mice per group from 3 representative experiments. Staining for donor MHC class II at these time points in the lung was negative for all groups. *P < 0.05 vs. non-KGF counterpart. ^P = 0.07 vs. non-KGF counterpart.



View larger version (83K):
[in this window]
[in a new window]
 
Fig. 10.   Immunoperoxidase staining for B7.1 expression of lung tissue taken on day 7 post-BMT of lethally irradiated B10.BR recipients pretreated with PBS (A) or KGF (days -6, -5, and -4; B) and transplanted with C57BL/6 BMS cells. Frozen sections were incubated with biotinylated anti-B7.1 monoclonal antibody (clone 1G10) and developed with peroxidase-conjugated avidin-biotin complex and diaminobenzidine chromogen (methyl green counterstain). Positive cells are indicated by solid arrows. Magnification ×100; resolution power is equivalent to ×40 objective lens.

We have described in a murine GVHD model that the cytolytic capacity of circulating alloreactive T cells is increased as is the expression of granzyme B that is induced upon activation of cytolytic cells (2). Because B7 expression on antigen-presenting cells is needed for efficient CTL generation and granzyme B is a mediator of CTL function, we sought to determine whether the attenuated expression of B7 by KGF would translate into attenuated induction of granzyme B in the lungs of transplanted mice. In situ hybridization analysis (Fig. 11) showed that KGF reduced the frequency of cells expressing mRNA for the induced granzyme B (P = 0.05 for BMS vs. BMS/KGF and P = 0.07 for BMS/Cy vs. BMS/Cy/KGF) while not affecting the frequency of cells positive for the constitutively expressed granzyme A mRNA. Representative photomicrographs of granzyme B mRNA staining are illustrated in Fig. 12. Therefore, although not affecting the composition of the pulmonary cellular infiltrate, KGF pretreatment may reduce its injury-inducing capacity by hindering the expression of molecules necessary for cytolytic cell function, such as granzyme B. 


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 11.   KGF decreases granzyme B expression as assessed by in situ hybridization using antisense digoxigenin-labeled riboprobes for granzymes A and B mRNA on lung cryosections taken day 7 post-allogeneic BMT. B10.BR recipient mice were preconditioned with TBI (day -1) with and without Cy (120 mg · kg-1 · day-1, days -3 and -2) and given C57BL/6 BM with 15 × 106 spleen cells (BMS) on the day of BMT (day 0). Groups received KGF (5 mg · kg-1 · day-1) on days -6, -5, and -4 pre-BMT. Data are expressed as percent of nucleated cells expressing the indicated mRNA in the lung as determined by counting 4 fields per lung section under light microscope. Mean values ± SE are for 2 or 3 mice per group from 2 representative experiments. *P < 0.05 vs. non-KGF counterpart. ^P = 0.07 vs. non-KGF counterpart.



View larger version (77K):
[in this window]
[in a new window]
 
Fig. 12.   In situ hybridization using anti-sense digoxigenin-labeled riboprobes for granzyme B mRNA on day 7 after allogeneic BMT of TBI BMS recipients pretreated with PBS (A) or KGF (B). Positive cells are indicated by solid arrows and were detected with alkaline phosphatase-conjugated antidigoxigenin antibody and 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium chromogen (no counterstain). Magnification ×100; resolution power is equivalent to ×40 objective lens.

KGF increases the expression of IL-4 and IL-13, suppressors of monocyte differentiation. Reduction of GVHD-induced lethality can be associated with the induction of counterregulatory cells (Th2) producing anti-inflammatory cytokines (such as IL-4 and IL-10) that skew the T-cell response away from inflammatory Th1 cytokine production (such as IL-2 and IFN-gamma ) (25). We wished to determine whether the beneficial effects of KGF [i.e., amelioration of GVHD and lung pathology (41), lowered B7 and granzyme B expression in the lung] were related to effects on circulating cytokine levels at the time of BMT when allogeneic donor T cells are infused (i.e., day 0). If so, one may expect either reduced levels of proinflammatory cytokines (IFN-gamma , TNF-alpha , and IL-1beta ) or increased levels of anti-inflammatory cytokines (such as IL-4, IL-10, and IL-13). Because the BM inoculum is administered intravenously on day 0, the cells would be exposed immediately to the cytokine milieu at this time point, which then may translate into a subsequent effect on the cells infiltrating the lung. Table 1 (pooled data from 4 experiments) shows the circulating levels of IL-4, IL-13, and IL-6 on day 0 immediately before BMT. One day postirradiation, TBI conditioning did not significantly increase cytokine levels. Interestingly, KGF pretreatment of TBI-conditioned mice did not affect IFN-gamma , TNF-alpha , IL-1beta , or IL-10 on day 0 (data not shown) but did significantly increase levels of several Th2 (anti-inflammatory) cytokines including IL-4, IL-6, and IL-13. The addition of Cy to the TBI conditioning increased the level of IL-6 on day 0 and decreased the level of IL-13 compared with control mice. KGF significantly increased the level of IL-13 in Cy/TBI recipients back to a level comparable to normal control mice. The increases in IL-4 and IL-13 were due solely to KGF and not an interaction with irradiation, since KGF-treated controls that were not irradiated had equivalent, elevated levels of these cytokines. There was, however, a multicomponent interaction to the increase in IL-6 seen in the TBI/KGF group, since the increased IL-6 level was significantly higher than the non-BMT KGF control group. These data indicate that at this day 0 time point, KGF pretreatment induced the production of Th2-like (or anti-inflammatory) cytokines, especially IL-13. In addition to Th2 cells, the other major producer of IL-13 is the alveolar macrophage (30); therefore, it is possible that these cells may have been the source of this serum IL-13. However, analysis of BAL fluids harvested on day 0 or day 3 post-BMT showed negligible levels of IL-13 (data not shown). Therefore, it appears that KGF is inducing Th2 cells to produce IL-13 (and perhaps IL-4), which can serve to downregulate macrophage differentiation and function.

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Day 0 serum cytokine level determinations


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We examined the use of KGF as a pretreatment therapy for IPS. IPS results from a combination of tissue damage and allogeneic T cell-dependent inflammatory events that occur in the early peri-BMT period in our established murine model. The effects of KGF pretreatment on lung repair entailed preservation of noninjured ATII cells on day 0 and apparent type II cell hyperplasia on day 3 post-BMT. More strikingly, the effects of KGF pretreatment on the immune response to lung injury were manifest as the attenuation of the expression of the T-cell costimulatory molecules B7.1 (CD80) and B7.2 (CD86) and a decrease in the frequency of cells transcribing mRNA for the inducible cytolytic molecule granzyme B. These decreases were not due to reduced cellular infiltration, since KGF did not change the composition of the lung-infiltrating cells on day 7 post-BMT and, furthermore, did not affect the frequency of cells transcribing the constitutive granzyme A mRNA.

KGF-treated mice exhibited lower frequencies of injured ATII cells on day 0, consistent with the cytoprotective effects of KGF on these cells. Because this is the time of BMT, the infused donor cells would be exposed to fewer injured cells, perhaps blunting their ensuing activation that normally occurs in IPS. Because the ability to repair the injured alveolar epithelium is dependent on the ability of type II cells to proliferate, differentiate, and replace type I cells, an epithelial cytoprotective agent such as KGF could potentially enhance this process. The apparent ATII cell hyperplasia seen in the KGF-pretreated mice at day 3 post-BMT is consistent with this hypothesis and with the lack of evident pathology in the lungs of long-term survivors of Cy/TBI-conditioned recipients of BMS (usually exhibiting the most severe injury and mortality) that were pretreated with KGF. We did not observe overt multifocal knobby proliferation of alveolar epithelial cells as shown by others (52) by light microscopy of hematoxylin and eosin-stained lung cryosections, but we did see occasional small clusters and diffuse cuboidal growth of ATII cells. These features have been demonstrated by Ulich et al. (52) and have been described as the later stages of KGF-mediated ATII cell proliferation by KGF given intratracheally. The route of KGF injection is most likely the reason for the lack of this overt type II cell sequela of KGF because we administered it subcutaneously as opposed to the intratracheal injection of KGF, which causes the formation of knobby cuboidal cell growth along the alveolar septa composed of proliferating type II cells. Consistent with our hypothesis, a recent study by Guo et al. (28) has shown that intravenous administration of KGF, while not causing overt type II cell proliferation, is still effective at preventing bleomycin- and hyperoxia-induced lung injury but not as potently as the intratracheal route. There is also recent evidence by Borok et al. (7) that KGF may cause a reversion of type I cells into cells with type II pneumocyte characteristics, making them more resistant to injury, a process termed reversible transdifferentiation. In vivo, this would translate into an increased number of type II cells.

The relevance of the decreased B7 expression in KGF-pretreated BMS recipient mice may relate to the decrease in cytolytic T-cell granzyme B expression. In the absence of costimulatory signals such as those mediated by B7 (on antigen-presenting cells) on binding to the CD28 counterreceptor (on T cells), antigen-triggered T cells become nonresponsive or anergic (8, 45). It is well established that B7 expression augments CTL generation (35). In our KGF-pretreated IPS model, the colocalization of donor T cells with monocytes expressing low levels of B7 may lead to a failure of conducive costimulation for an allo-MHC response resulting in the observed lower frequency of cytolytic cells in situ. This is consistent with our recent observations that preclusion of the CD28-B7 interaction by anti-B7 MAb reduced the generation of granzyme B-positive cells and the in vitro cytolytic activity of T cells obtained from MHC-disparate irradiated recipients of allogeneic T cells (2). Because of the apparent preservation of the type II cells by KGF, the lower level of B7 and granzyme B expression may be sequelae of the reduced damage resulting in less immune activation.

Sera from KGF-treated mice exhibited increased levels of the Th2 cytokines IL-4, IL-6, and especially IL-13 4 days after cessation of KGF administration (day 0) even in the absence of irradiation or BMT. This argues that at least some of the effects of KGF may be independent of the sequelae of reduced lung injury. Because day 0 is the time at which the BM inoculum is administered, these cells would be immediately exposed to this Th2 type of cytokine environment in the circulation into which the cells are infused. It has recently been demonstrated that the functional response of bone marrow-derived macrophages is determined by the first exposure to cytokine, thereby rendering them unresponsive to subsequent exposure to alternate cytokines (21). Several studies have demonstrated that IL-13 can suppress many monocyte activities, similar to IL-4 (1, 14, 16-18, 36, 37, 48, 59). The downregulation of CD14 (LPS receptor) expression by IL-13 (14) may, in part, explain the survival of KGF-pretreated BMT recipients in the face of GVHD-induced colitis (41). Damage to other GVHD target organs, particularly the gastrointestinal tract, induces the systemic release of endotoxin (LPS) that primes monocytes to release proinflammatory cytokines that exacerbate GVHD and IPS (12). Because our data suggest that KGF pretreatment leads to decreased monocyte activation, KGF also may protect the BMT recipient against adverse consequences of monocyte activation that contribute to lung injury.

IL-13 does not affect the chemotactic properties of monocytes (61), and we found no difference in the infiltration of monocytes into the lung on day 7 post-BMT with KGF treatment. We do not yet know whether the decreased expression of B7 molecules by these monocytes is due to direct KGF effects or indirect effects via the inhibitory effects of IL-13; the effect of IL-13 on monocyte-B7 expression has not been addressed in the literature. Decreased monocyte function would explain the decreased inflammatory (IFN-gamma , data not shown) and cytotoxic (granzyme B) T-cell mediators we found in the lungs of KGF-pretreated BMS recipients at day 7 post-BMT. These recipients also had significantly lower levels of serum TNF-alpha than non-KGF-treated counterparts on day 7 post-BMT (data not shown) consistent with the recent observations of Krijanovski et al. (34) using another murine GVHD model. The association of lower TNF-alpha and LPS levels with less severe manifestations of GVHD and lung injury post-BMT suggests that TNF-alpha and LPS contribute to IPS injury. The source of the Th2-type cytokines found in the serum of KGF-treated mice on day 0 just before BMT is most likely Th2 cells for the following reasons: 1) aside from alveolar macrophages, Th2 cells are the only known major producers of IL-13, and BAL fluid IL-13 levels did not parallel serum levels; 2) IL-4 is produced primarily by activated Th2 cells; and 3) IL-1beta and TNF-alpha , monocyte products, were not increased at this time point. Although IL-6 also was elevated in response to KGF, it can be produced by numerous cells including keratinocytes, which likely were activated in response to the subcutaneous injection of KGF. In addition, T cells costimulated by activated keratinocytes preferentially produce IL-4 (27), and IL-4 was elevated in response to KGF pretreatment in our study. Of note, IL-13 can also have proinflammatory properties depending on the target cell (19, 29) and the timing of the exposure of the monocyte to IL-13 in relation to the stimulus (i.e., antigen) (15). In fact, high levels of monocyte-derived IL-13 are found in the BAL fluid of asthmatics (32) and patients with pulmonary fibrosis (30). Perhaps the latter are examples of failed attempts at repair. Numerous reports have shown that type 2 alloreactive T cells, generally considered to be anti-inflammatory, have a reduced capacity to induce GVHD (25, 33). However, this may not be a universal finding in GVHD (38). We do not know whether the amelioration of IPS by KGF is Th2 dependent.

Taken together, these data suggest that KGF can hinder IPS by two modes: 1) enhancement of alveolar epithelialization and 2) attenuation of B7 and cytolytic molecule (granzyme B) expression in situ, possibly via induction of Th2 cytokines, in particular IL-13, a potent macrophage downregulator, thus enabling lung repair.


    ACKNOWLEDGEMENTS

The expert technical assistance of John Hermanson, Sumiko Yoneji, Claudia DeLlano, Chris Lees, Naomi Fujioka, Stacey Hermanson, and Kelly Coffey is greatly appreciated. We also thank Dr. Patricia A. Taylor for helpful discussions.


    FOOTNOTES

This study was supported by National Heart, Lung, and Blood Institute (NHLBI) Grant HL-55209; Morphology Core of the NHLBI Specialized Center of Research in Acute Lung Injury Grant HL-50152; the Minnesota Medical Foundation; and the Viking Children's Fund.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Address for reprint requests and other correspondence: A. Panoskaltsis-Mortari, Dept. of Pediatrics, Div. of Hematology-Oncology and Blood Marrow Transplantation, Univ. of Minnesota, Box 366 MAYO, 420 Delaware St. SE, Minneapolis, MN 55455 (E-mail: panos001{at}tc.umn.edu).

Received 5 August 1999; accepted in final form 9 December 1999.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Berkman, N, John M, Roesems G, Jose P, Barners PJ, and Chung KF. Interleukin-13 inhibits macrophage inflammatory protein-1alpha production from human alveolar macrophages and monocytes. Am J Respir Cell Mol Biol 15: 382-389, 1996[Abstract].

2.   Blazar, BR, Sharpe AH, Taylor PA, Panoskaltsis-Mortari A, Gray G, Korngold R, and Vallera DA. The infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ cells. J Immunol 157: 3250-3259, 1996[Abstract].

3.   Blazar, BR, Taylor PA, Linsley PS, and Vallera DA. In vivo blockade of CD28/CTLA4:B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-vs.-host disease across the major histocompatibility complex (MHC) barrier in mice. Blood 83: 3815-3825, 1994[Abstract/Free Full Text].

4.   Blazar, BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, and Vallera DA. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 85: 2607-2618, 1995[Abstract/Free Full Text].

5.   Blazar, BR, Taylor PA, Snover DC, Bluestone JA, and Vallera DA. Nonmitogenic anti-CD3 F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier. J Immunol 150: 265-277, 1993[Abstract/Free Full Text].

6.   Borok, Z, Danto SI, Dimen LL, Zhang X-L, and Lubman RL. Na+-K+-ATPase expression in alveolar epithelial cells: upregulation of active ion transport by KGF. Am J Physiol Lung Cell Mol Physiol 274: L149-L158, 1998[Abstract/Free Full Text].

7.   Borok, Z, Lubman RL, Danto SI, Zhang X-L, Zabski SM, King LS, Lee DM, Agre P, and Crandall EC. Keratinocyte growth factor modulates alveolar epithelial cell phenotype in vitro: expression of aquaporin 5. Am J Respir Cell Mol Biol 18: 554-561, 1998[Abstract/Free Full Text].

8.   Boussiotis, VA, Freeman GJ, Gray G, Gribben J, and Nadler LM. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 178: 1753-1763, 1993[Abstract].

9.   Clark, JG, Hansen JA, Hertz MI, Parkman R, Jensen L, and Peavy HH. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 147: 1601-1606, 1993[ISI][Medline].

10.   Clark, JG, Madtes DK, Hackman RC, Chen W, Cheever MA, and Martin PJ. Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell inflammation and activation of alveolar macrophages. J Immunol 161: 1913-1920, 1998[Abstract/Free Full Text].

11.   Clift, RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LB, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, and Thomas ED. Allogeneic marrow transplantation in patients with acute leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76: 1867-1871, 1990[Abstract].

12.   Cooke, KR, Kobzik L, Martin TR, Brewer J, Delmonte J, Jr, Crawford JM, and Ferrara JLM An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood 88: 3230-3239, 1996[Abstract/Free Full Text].

13.   Cooke, KR, Krenger W, Hill G, Martin TR, Kobzik L, Brewer J, Simmons R, Crawford JM, van der Brink MRM, and Ferrara J. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood 92: 2571-2580, 1998[Abstract/Free Full Text].

14.   Cosentino, G, Soprana E, Thienes CP, Siccardi AG, Viale G, and Vercelli D. IL-13 down-regulates CD14 expression and TNF-alpha secretion in normal human monocytes. J Immunol 155: 3145-3151, 1995[Abstract].

15.   D'Andrea, A, Ma X, Aste-Amezaga M, Pagnin C, and Trinchieri G. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha  production. J Exp Med 181: 537-546, 1995[Abstract].

16.   Del Prete, G, De Carli M, Lammel RM, D'Elios MM, Daniel KC, Giusti B, Abbate R, and Romagnani S. Th1 and Th2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood 86: 250-257, 1995[Abstract/Free Full Text].

17.   De Vries, JE, and Zurawski G. Immunoregulatory properties of IL-13: its potential role in atopic disease. Int Arch Allergy Immunol 106: 175-179, 1995[ISI][Medline].

18.   De Waal Malefyt, R, Figdor CG, Huijbens R, Mohan-Petersen S, Bennett B, Culpepper J, Dang W, Zurawski G, and de Vries JE. Effects of IL-13 on phenotype, cytokine production and cytotoxic function of human monocytes. J Immunol 151: 6370-6381, 1993[Abstract/Free Full Text].

19.   Di Santo, E, Meazza C, Sironi M, Fruscella P, Mantovani A, Sipe JD, and Ghezzi P. IL-13 inhibits TNF production but potentiates that of IL-6 in vivo and ex vivo in mice. J Immunol 159: 379-382, 1997[Abstract].

20.   Down, JD, Mauch P, Warhol M, Neben S, and Ferrara JLM The effect of donor T lymphocytes and total-body irradiation on hemopoietic engraftment and pulmonary toxicity following experimental allogeneic bone marrow transplantation. Transplantation 54: 802-808, 1992[ISI][Medline].

21.   Erwig, L-P, Kluth DC, Walsh GM, and Rees AJ. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol 161: 1983-1988, 1998[Abstract/Free Full Text].

22.   Farrell, CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu Z-N, Aukerman SL, Pierce GF, Thomason A, Potten CS, Ulich TR, and Lacey DL. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58: 933-939, 1998[Abstract].

23.   Finch, PW, Cunha GR, Rubin JS, Wong J, and Ron D. Pattern of keratinocyte growth factor and keratinocyte growth factor receptor expression during mouse fetal development suggests a role in mediating morphogenetic mesenchymal-epithelial interactions. Dev Dyn 203: 223-240, 1995[ISI][Medline].

24.   Finch, PW, Rubin SS, Miki T, Ron D, and Aaronson SA. Human KGF is FGF-related with properties of a paracrine effector of epithelial growth. Science 245: 752-755, 1989[ISI][Medline].

25.   Fowler, DH, Kurasawa K, Husebekk A, Cohen PA, and Gress RE. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 152: 1004-1010, 1994[Abstract/Free Full Text].

26.   Gassmann, W, Uharek L, Wottge H-U, Schmitz N, Loffler H, and Mueller-Ruchholtz W. Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation. Blood 72: 1574-1579, 1988[Abstract].

27.   Goodman, RE, Nestle F, Naidu YM, Green JM, Thompson CB, Nickoloff BJ, and Turka LA. Keratinocyte-derived T cell costimulation induces preferential production of IL-2 and IL-4 but not IFN-gamma . J Immunol 152: 5189-5198, 1994[Abstract/Free Full Text].

27a.   Gross, NJ. The pathogenesis of radiation-induced lung damage. Lung 159: 115-125, 1981[ISI][Medline].

28.   Guo, J, Yi ES, Havill AM, Sarosi I, Whitcomb L, Yin S, Middleton SC, Piguet P, and Ulich TR. Intravenous keratinocyte growth factor protects against experimental pulmonary injury. Am J Physiol Lung Cell Mol Physiol 275: L800-L805, 1998[Abstract/Free Full Text].

29.   Halloran, MM, Haskell CJ, Woods JM, Hosaka S, and Koch AE. Interleukin-13 is an endothelial chemotaxin. Pathobiology 65: 287-292, 1997[ISI][Medline].

30.   Hancock, A, Armstrong L, Gama R, and Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 18: 60-65, 1998[Abstract/Free Full Text].

31.   Holler, E, Kolb HJ, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mittermuller J, and Wilmanns W. Increased serum levels of tumor necrosis factor-alpha precede major complications of bone marrow transplantation. Blood 75: 1011-1016, 1990[Abstract].

32.   Huang, SK, Xiao HQ, Kleine-Tebbe J, Paciotti G, Marsh DG, Lichtenstein LM, and Liu MC. IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 155: 2688-2694, 1995[Abstract].

33.   Krenger, W, Snyder KM, Byon JC, Falzarano G, and Ferrara JL. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental graft-versus-host disease. J Immunol 155: 585-593, 1995[Abstract].

34.   Krijanovski, OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS, and Ferrara JLM Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 94: 825-831, 1999[Abstract/Free Full Text].

35.   Lenschow, DJ, Walunas TL, and Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 114: 233-258, 1996.

36.   Levesque, MC, and Haynes BF. Cytokine induction of the ability of human monocyte CD44 to bind hyaluronan is mediated primarily by TNF-alpha and is inhibited by IL-4 and IL-13. J Immunol 159: 6184-6194, 1995[Abstract].

37.   Minty, A, Chalon P, Derocq JM, Dumont X, Guillemot J, Kaghad M, Labit C, Leplatois P, Liauzun P, Muoux B, Minty C, Casellas P, Loison G, Lupker J, Shire D, Ferrara P, and Caput D. Interleukin-13 is a new lymphokine regulating inflammatory and immune responses. Nature 362: 248-250, 1993[ISI][Medline].

38.   Murphy, WJ, Welniak LA, Taub DD, Wiltrout R, Taylor PA, Vallera DA, Kopf M, Longo DL, and Blazar BR. Differential effects on the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 102: 1742-1748, 1998[Abstract/Free Full Text].

39.   Panos, RJ, Rubin JS, Aaronson SA, and Mason RJ. Keratinocyte growth factor and hepatocyte growth factor scatter factor are heparin-binding growth factors for alveolar type II cells in fibroblast-conditioned medium. J Clin Invest 92: 969-977, 1993[ISI][Medline].

40.   Panoskaltsis-Mortari, A, and Bucy RP. In situ hybridization with digoxigenin-labeled RNA probes: facts and artifacts. Biotechniques 18: 300-308, 1995[ISI][Medline].

41.   Panoskaltsis-Mortari, A, Lacey DL, Vallera DA, and Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 10: 3960-3967, 1998.

42.   Panoskaltsis-Mortari, A, Taylor PA, Yaeger TM, Wangensteen OD, Bitterman PB, Ingbar DH, Vallera DA, and Blazar BR. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. J Clin Invest 100: 1015-1027, 1997[Abstract/Free Full Text].

43.   Petersen, FB, Deeg HJ, Buckner CD, Appelbaum FR, Storb R, Clift RA, Sanders JE, Bensinger WI, Witherspoon RP, Sullivan M, Doney D, and Hansen JA. Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide: a phase I study. Int J Radiat Oncol Biol Phys 23: 1027-1032, 1992[ISI][Medline].

44.   Piguet, PF, Grau GE, Collart MA, Vassalli P, and Kapanci Y. Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab Invest 61: 37-45, 1989[ISI][Medline].

45.   Schwartz, RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065-1068, 1992[ISI][Medline].

46.   Shankar, G, Bryson JS, Jennings CD, Morris PE, and Cohen DA. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation. Am J Respir Cell Mol Biol 18: 235-242, 1998[Abstract/Free Full Text].

47.   Soderling, CCB, Song CW, Blazar BR, and Vallera DA. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants. J Immunol 135: 941-946, 1985[Abstract/Free Full Text].

48.   Sozzani, P, Cambon C, Vita N, Séguélas MH, Caput D, Ferrara P, and Pipy B. Interleukin-13 inhibits protein kinase C-triggered respiratory burst in human monocytes. J Biol Chem 270: 5084-5088, 1995[Abstract/Free Full Text].

49.   Sugahara, K, Rubin JS, Mason RJ, Aronson EL, and Shannon JM. Keratinocyte growth factor increases mRNAs for SP-A and SP-B in adult rat alveolar type II cells in culture. Am J Physiol Lung Cell Mol Physiol 269: L344-L350, 1995[Abstract/Free Full Text].

50.   Takeoka, M, Ward WF, Pollack H, Kamp DW, and Panos RJ. KGF facilitates repair of radiation-induced DNA damage in alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 272: L1174-L1180, 1997[Abstract/Free Full Text].

51.   Ulich, TR, Whitcomb L, Tang W, O'Connor Tressel P, Tarpley J, Yi ES, and Lacey D. Keratinocyte growth factor ameliorates cyclophosphamide-induced ulcerative hemorrhagic cystitis. Cancer Res 57: 472-475, 1997[Abstract].

52.   Ulich, TR, Yi ES, Longmuir K, Yin S, Blitz R, Morris CF, Housley RM, and Pierce GF. Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest 93: 1298-1306, 1994[ISI][Medline].

53.   Ulich, TR, Yi ES, Yin S, Smith C, and Remick D. Intratracheal administration of endotoxin and cytokines. VII. The soluble interleukin-1 receptor and the soluble tumor necrosis factor receptor II (p80) inhibit acute inflammation. Clin Immunol Immunopathol 72: 137-140, 1994[ISI][Medline].

54.   Ulich, TR, Yin S, Remick DG, Russell D, Eisenberg SP, and Kohno T. Intratracheal administration of endotoxin and cytokines. IV. The soluble tumor necrosis factor receptor type I inhibits acute inflammation. Am J Pathol 142: 1335-1338, 1993[Abstract].

55.   Weiner, RS, Bortin MM, Gale RP, Gluckmann E, Kay HEM, Kolb JH, Hartz AJ, and Rimm AA. Interstitial pneumonitis after bone marrow transplantation: assessment of risk factors. Ann Intern Med 104: 168-175, 1986[ISI][Medline].

56.   Werner, S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev 9: 153-165, 1998[ISI][Medline].

57.   Wu, KI, Pollack N, Panos RJ, Sporn PHS, and Kamp DW. Keratinocyte growth factor promotes alveolar epithelial cell DNA repair after H2O2 exposure. Am J Physiol Lung Cell Mol Physiol 275: L780-L787, 1998[Abstract/Free Full Text].

58.   Xing, Z, Jordana M, Kirpalani H, Driscoll KE, Schall TJ, and Gauldie J. Cytokine expression by neutrophils and macrophages in vivo: endotoxin induces tumor necrosis factor-alpha , macrophage inflammatory protein-2, interleukin-1beta , and interleukin-6 but not RANTES or transforming growth factor-beta mRNA expression in acute lung inflammation. Am J Respir Cell Mol Biol 10: 148-153, 1994[Abstract].

59.   Yanagawa, H, Sone S, Haku T, Mizuno K, Yano S, Ohmoto Y, and Ogura T. Contrasting effect of interleukin-13 on interleukin-1 receptor antagonist and proinflammatory cytokine production by human alveolar macrophages. Am J Respir Cell Mol Biol 12: 71-76, 1995[Abstract].

60.   Yano, T, Deterding R, Simonet WS, Shannon JM, and Mason RJ. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol 15: 433-442, 1996[Abstract].

61.   Yano, S, Sone S, Nishioka Y, Mukaida N, Matsushima K, and Ogura T. Differential effects of anti-inflammatory cytokines (IL-4, IL-10 and IL-13) on tumoricidal and chemotactic properties of human monocytes induced by monocyte chemotactic and activating factors. J Leukoc Biol 57: 303-309, 1995[Abstract].

62.   Yi, ES, Williams ST, Lee H, Malicki DM, Chin EM, Yin S, Tarpley J, and Ulich TR. Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality. Am J Pathol 149: 1963-1970, 1996[Abstract].


Am J Physiol Lung Cell Mol Physiol 278(5):L988-L999
1040-0605/00 $5.00 Copyright © 2000 the American Physiological Society